Vancouver, British Columbia–(Newsfile Corp. – June 10, 2021) – Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (“Entheon” or the “Company”), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced its Psychedelics Genetic Test Kit, developed by its wholly-owned subsidiary, HaluGen Life Sciences Inc. (“HaluGen”), is now available for sale in…
